Physician profile
Jasung Kim
NPI 1134235484
$5,875.25
in general payments reported to CMS, 2019-2025
11 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.14 · 2020: $57.56 · 2021: $408 · 2022: $2,001 · 2023: $832 · 2024: $1,263 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.35 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,060.32 | 2021-2025 | |
| Neuronetics, INC. | $1,351.35 | 2022 | |
| Alkermes, INC. | $813.71 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $509.80 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $457.56 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $254.80 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $155.33 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $115.98 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $113.18 | 2019-2021 | |
| Neos Therapeutics, LP | $22.90 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.